Evaluating the Role of COVID-19 Vaccines in Patient Outcomes
Authors:
- 29 January 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 33 (2)
Abstract
Background: The recent SARS-CoV-2 pandemic posed a significant threat to human life. Vaccines played an unprecedented role in managing adverse outcomes, but the virus's ability to mutate and produce new variants posed ongoing challenges. This research aimed to examine the association between different types and numbers of doses of COVID-19 vaccinations and the clinical and demographic characteristics of patients. Methods: This retrospective cross-sectional study was carried out on 161 COVID-19 patients hospitalized at Afzalipour Hospital in Kerman, Iran, during the eighth wave of the pandemic. Data on demographic features, symptoms, patient status, disease outcome, and vaccination history of patients were collected. Results: Most patients (over 75%) had received 2 or 3 doses of the vaccine. Vaccination type and the number of doses showed significant differences based on patient gender (P = 0.048) and age group (P = 0.034), respectively. Shortness of breath showed significant differences based on the type of vaccine received (P = 0.0178). Fatigue substantially differed based on the number of vaccine doses (P = 0.03975). There were no significant differences in gastrointestinal symptoms, patient or disease status based on the number or type of vaccines, but lower death rates were observed in vaccinated patients. Additionally, while trends indicated better outcomes with a higher number of vaccine doses, there were no significant variations in blood oxygen saturation (SpO2) or respiratory rate based on the type or number of vaccine doses. Conclusions: The findings highlight the role of vaccination in managing COVID-19 outcomes despite the reduction of vaccine efficacy against emerging variants.Keywords
This publication has 18 references indexed in Scilit:
- Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomesJournal of Infection, 2024
- Therapeutic strategies for COVID-19: progress and lessons learnedNature Reviews Drug Discovery, 2023
- Excess cardiovascular mortality across multiple COVID-19 waves in the United States from March 2020 to March 2022Nature Cardiovascular Research, 2023
- Food Insecurity and Economic Hardship of College Students: Before and during the COVID-19 PandemicJournal of Poverty, 2022
- Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in AdultsNew England Journal of Medicine, 2022
- Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in QatarNew England Journal of Medicine, 2022
- Duration of Protection against Mild and Severe Disease by Covid-19 VaccinesNew England Journal of Medicine, 2022
- Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralizationNature, 2021
- Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease SeverityJAMA, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 MonthsNew England Journal of Medicine, 2021